Necrostatin-1

Name: Necrostatin-1
Brand: Selleck Chemicals
SKU: S8037
Rating: 5 (80 reviews)

For research use only.

Catalog No.S8037

80 publications

CAS No. 4311-88-0

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.

Selleck's Necrostatin-1 has been cited by 80 publications

Haematologica, 2021, 10.3324/haematol.2020.259531

PubMed: 33406814 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E243

PubMed: 33440739 ( click the link to review the publication )

Sci Adv, 2020, 25;6(13):eaay9789

PubMed: 32232155 ( click the link to review the publication )

Part Fibre Toxicol, 2020, 17(1):46

PubMed: 32948194 ( click the link to review the publication )

Redox Biol, 2020, 38:101777

PubMed: 33166869 ( click the link to review the publication )

J Med Chem, 2020, 63(17):9838-9855

PubMed: 32809827 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):781

PubMed: 32951003 ( click the link to review the publication )

Cell Death Dis, 2020, 22;11(5):391

PubMed: 32444644 ( click the link to review the publication )

Mol Nutr Food Res, 2020, 1;e1901231

PubMed: 32476238 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:1295382

PubMed: 33123307 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 4;2020:5021983

PubMed: 32322335 ( click the link to review the publication )

Oncogenesis, 2020, 9(10):94

PubMed: 33093450 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(12)E4204

PubMed: 32545631 ( click the link to review the publication )

J Biol Chem, 2020, 1;295(18):6236-6248

PubMed: 32179652 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0376-8

PubMed: 32132657 ( click the link to review the publication )

Front Pharmacol, 2020, 11:812

PubMed: 32595496 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 8;521(2):414-419

PubMed: 31672277 ( click the link to review the publication )

Med Sci Monit, 2020, 26:e919739

PubMed: 32019905 ( click the link to review the publication )

Biosci Biotechnol Biochem, 2020, 18;1-8

PubMed: 32419644 ( click the link to review the publication )

Front Pharmacol, 2020, 11:812

PubMed: 32595496 ( click the link to review the publication )

Sci Total Environ, 2020, 699:134296

PubMed: 31683218 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):635

PubMed: 32801338 ( click the link to review the publication )

Cell Rep, 2020, 30(1):25-36

PubMed: 31914391 ( click the link to review the publication )
Cell Death Discov, 2020, 6:67

PubMed: 32793397 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100034

PubMed: 32793892 ( click the link to review the publication )

PLoS Pathog, 2020, 16(7):e1008473

PubMed: 32649716 ( click the link to review the publication )

Blood Adv, 2020, 4(22):5666-5680

PubMed: 33211827 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):630

PubMed: 32801360 ( click the link to review the publication )

Int J Oncol, 2020, 56(2):439-447

PubMed: 31894265 ( click the link to review the publication )

J Clin Invest, 2019, 129(6):2431-2445

PubMed: 31081803 ( click the link to review the publication )

EMBO Rep, 2019, 20(10):e47840

PubMed: 31410978 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0274-0

PubMed: 30760873 ( click the link to review the publication )

Front Oncol, 2019, 9:436

PubMed: 31192135 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2902

PubMed: 30814594 ( click the link to review the publication )

J Biol Chem, 2019, 10.1074/jbc.RA119.010379

PubMed: 31723031 ( click the link to review the publication )

Front Mol Neurosci, 2019, 12:222

PubMed: 31607859 ( click the link to review the publication )

Int J Mol Med, 2019, 43(2):967-979

PubMed: 30569134 ( click the link to review the publication )

Cell Transplant, 2019, 28(11):1358-1372

PubMed: 31370690 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6678-6690

PubMed: 31803362 ( click the link to review the publication )

Mol Metab, 2019, 23:14-23

PubMed: 30837196 ( click the link to review the publication )

J Hepatol, 2018, 68(6):1228-1238

PubMed: 29408314 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1680

PubMed: 29700283 ( click the link to review the publication )

Autophagy, 2018, 14(5):778-795

PubMed: 29171784 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Oncogene, 2018, 37(29):4033-4045

PubMed: 29706658 ( click the link to review the publication )

Oncoimmunology, 2018, 7(6):e1431086

PubMed: 29872558 ( click the link to review the publication )
Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1514-1527

PubMed: 30210920 ( click the link to review the publication )

Ann Biomed Eng, 2018, 46(7):1013-1025

PubMed: 29603044 ( click the link to review the publication )

Toxicology, 2018, 406-407:33-43

PubMed: 29860048 ( click the link to review the publication )

Am J Transl Res, 2018, 10(5):1357-1372

PubMed: 29887951 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):3051-3062

PubMed: 29436589 ( click the link to review the publication )

Int J Med Sci, 2018, 15(14):1648-1657

PubMed: 30588188 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):43

PubMed: 29970185 ( click the link to review the publication )

Cancer Lett, 2017, 381(1):96-103

PubMed: 27477897 ( click the link to review the publication )

Cancer Lett, 2017, 402:81-92

PubMed: 28576750 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2765

PubMed: 28471454 ( click the link to review the publication )

Genes Chromosomes Cancer, 2017,

PubMed: 28177558 ( click the link to review the publication )

Cell Cycle, 2017, 16(4):348-359

PubMed: 27929749 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(4):659-70

PubMed: 27050456 ( click the link to review the publication )

Autophagy, 2016, 12(10):1738-1758

PubMed: 27463126 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0523

PubMed: 27302164 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 8;35(1):192

PubMed: 27931237 ( click the link to review the publication )

Free Radical Biology and Medicine, 2016, S0891-5849(16)00114-3

PubMed: 27012422 ( click the link to review the publication )

Sci Rep, 2016, 6:24245

PubMed: 27095146 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):1135-42

PubMed: 27349281 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27014915 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47387-47402

PubMed: 27329722 ( click the link to review the publication )
Oncotarget, 2016, 7(25):38718-38730

PubMed: 27231850 ( click the link to review the publication )

Mutat Res, 2016, 789:1-8

PubMed: 27155559 ( click the link to review the publication )

Genet Mol Res, 2016, 10.4238/gmr.15027298

PubMed: 27323061 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2199

PubMed: 25724678 ( click the link to review the publication )

J Cell Mol Med, 2015, 10.1111/jcmm.12495

PubMed: 25754842 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134144

PubMed: 26270345 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0122083

PubMed: 25894744 ( click the link to review the publication )

Oncotarget, 2015, 6(15):13476-86

PubMed: 25974963 ( click the link to review the publication )

Purity & Quality Control

Choose Selective RIP kinase Inhibitors

Biological Activity

Description

Features

A powerful tool for characterizing the role of necroptosis with characterized primary target.

Targets

RIP1 ^[1]
(293T cells)

490 nM(EC50)

In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. ^[1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT-22	MlfsR5l1d3SxeHnjbZR6KEG\|c3H5	MnXBNVAh\|ryP	NEn2c3kyOiCq		M4XrTJBzd3SnY4TzJIFo[Wmwc4SgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KDYEoH3tc4wwVCCpbIX0ZY1ifGYEoB?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzd4MEi2PUc,OTd5NkC4Olk9N2F-
Jurkat	NEPEcY5HfW6ldHnvckBCe3OjeR?=	MYqyNFDDqM7:bR?=	MXezNEBucW5?		NEf0OIxz\WS3Y3XzxsBP[WWpbHXybYEh\m:5bHXybU1qdmS3Y3XkJJJm[WO2aY\lJI95gWenbjDzdIVkcWW\|IDjSU3MqKGenbnXyZZRqd25?	NF7KXZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWzOVAzOCd-MkG1N\|UxOjB:L3G+
Jurkat	MYjDfZRwfG:6aXPpeJkhSXO\|YYm=	NWfZUVZnPTBxIEGwNE8zODEEoN88cS=>	MY[xM\|MhcA>?		NWj2PYlvemWmdXPld:KhVmGnZ3zldoliKG[xd3zldokucW6mdXPl[EBkgXSxdH;4bYNqfHl?	MmrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3M{WwNlAoRjJzNUO1NFIxRC:jPh?=
SW13	M2D6RmNmdGxiVnnhZoltcXS7IFHzd4F6	MonENVAxKM7:TR?=	NIXzeGMzPCCq	M3H0cmROW09?	MoHHbY5kemWjc3XzJINmdGy3bHHyJJN2en[rdnHs	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF\|NkixPEc,OjJzM{[4NVg9N2F-
8505c	MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGTBTogyODBizszN	NYfXd4N1OjRiaB?=	NYjVR4NUTE2VTx?=	MVHpcoNz\WG\|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy=	Mn\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzM{[4NVgoRjJ{MUO2PFE5RC:jPh?=
TPC-1	NVrKeI5iS2WubDDWbYFjcWyrdImgRZN{[Xl?	NUHMcXg3OTByIN88US=>	M33Rb\|I1KGh?	NEfOcFBFVVOR	MYHpcoNz\WG\|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF\|NkixPEc,OjJzM{[4NVg9N2F-
L929sA	M2j3RmFxd3C2b4Ppd{BCe3OjeR?=	NHTHWngyOCEQvF2=	NHqzblIyKGh?		MWLhZpJw\2G2ZYOgeIhmKGmwdHXyZYN1cW:wIH;mJINie3Cjc3WtPEB4cXSqIF\BSGQ>	Mn7hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NkK3OlcoRjJ{M{[yO\|Y4RC:jPh?=
L929sA	Ml\JRZBweHSxc3nzJGF{e2G7	NFe0PYwyOCEQvF2=	MYSxJIg>		Mne1doV{[3WnczDj[YxteyCneIDy[ZN{cW6pIGLJVGsy\|pSLRDDmdo9uKFSQRj3pcoR2[2WmIHHwc5B1d3Orcx?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4Mke2O{c,OjJ\|NkK3Olc9N2F-
L929sA	MnLLRZBweHSxc3nzJGF{e2G7	MWqxNEDPxE1?	NIP0c\|QyKGh?		M{PndolvcGmkaYTzJJRp\SCjcH;weI91cWNicnXzdI9ve2VidH:gWG5H	NV\n[I1NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlI4PjdpPkKyN\|YzPzZ5PD;hQi=>
K562/Adr	M{jvS2Z2dmO2aX;uJGF{e2G7	NG[wU3E3OCEQvF2=	M2W2T\|EzKGh?		M33IXIlv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG\|ZYOsJINie3Cjc3WgPEBidmRiOR?=	M36x[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3Olg6Lz5{MkizO\|Y5QTxxYU6=
K562	NXS3XYd6TnWwY4Tpc44hSXO\|YYm=	NF;qb483OCEQvF2=	NHrwZXcyOiCq		MVLpcoNz\WG\|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W\|LDDjZZNx[XOnIEigZY5lKDl?	M33YSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3Olg6Lz5{MkizO\|Y5QTxxYU6=
HL60/Adr	NWHOSnlCTnWwY4Tpc44hSXO\|YYm=	MnzCOlAh\|ryP	NUTNWGZLOTJiaB?=		NHPFdYVqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm=	NH3tbJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO\|Y5QSd-MkK4N\|c3QDl:L3G+
HL60	NFq1RZpHfW6ldHnvckBCe3OjeR?=	NV;6VWw{PjBizszN	NFW3V5IyOiCq		NH35PZpqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm=	NX20b5BMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N\|c3QDlpPkKyPFM4Pjh7PD;hQi=>
K562/Adr	M2L2SmZ2dmO2aX;uJGF{e2G7	NXTJU3U4PjBizszN	MU[xNkBp		MnTjZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>?	M1X0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3Olg6Lz5{MkizO\|Y5QTxxYU6=
K562	NYfzW4ZCTnWwY4Tpc44hSXO\|YYm=	MWq2NEDPxE1?	MUexNkBp		NH7WRnlifWevZX70d{B1cGViY3HzdIF{\S1\|IHHjeIl3cXS7	MoPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{e2PFkoRjJ{OEO3Olg6RC:jPh?=
HL60/Adr	NHXJT4hHfW6ldHnvckBCe3OjeR?=	MnrPOlAh\|ryP	MnPFNVIhcA>?		NYDSZ4lO[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?=	NH7rRo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO\|Y5QSd-MkK4N\|c3QDl:L3G+
HL60	NUSw[plXTnWwY4Tpc44hSXO\|YYm=	NXvFPJlPPjBizszN	Ml7GNVIhcA>?		MUfheYdu\W62czD0bIUh[2G\|cHHz[U0{KGGldHn2bZR6	NHvBcnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO\|Y5QSd-MkK4N\|c3QDl:L3G+
K562/Adr	MVTBdI9xfG:\|aYOgRZN{[Xl?	NE\1cpA3OCEQvF2=	NGXTSJcyOiCq		NXXLcll5\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM>	M3:5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3Olg6Lz5{MkizO\|Y5QTxxYU6=
K562	M3z0SWFxd3C2b4Ppd{BCe3OjeR?=	NFn5PWE3OCEQvF2=	MWGxNkBp		MYflcohidmOnczDzbIlsd26rbj3pcoR2[2WmIHHwc5B1d3Orcx?=	M2DaXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3Olg6Lz5{MkizO\|Y5QTxxYU6=
HL60/Adr	M3TzOmFxd3C2b4Ppd{BCe3OjeR?=	NFrQfHQ3OCEQvF2=	M33kNFEzKGh?		MUXlcohidmOnczDzbIlsd26rbj3pcoR2[2WmIHHwc5B1d3Orcx?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh\|N{[4PUc,OjJ6M{e2PFk9N2F-
HL60	NGnUSIZCeG:ydH;zbZMhSXO\|YYm=	MXW2NEDPxE1?	NFzHSGoyOiCq		MnPn[Y5p[W6lZYOgd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:\|aYO=	M2XUdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO3Olg6Lz5{MkizO\|Y5QTxxYU6=
SH-EP	NEDweJRCeG:ydH;zbZMhSXO\|YYm=	M4TNPVEx6oDLzszNxsA>	NWnkOVdbPzMkgJnoxsA>		MkWxbY5pcWKrdIOgTWFRKGmwaHnibZRwei1iYX7kJGxmgGG2dX31cYFjNWmwZIXj[YQh[XCxcITvd4l{	M4L6VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEmwN\|IzLz5{Mki5NFMzOjxxYU6=
NIH3T3	MorJSpVv[3Srb36gRZN{[Xl?	M1rzNVExNzVyIN88US=>	Mn\XNU8{KGh?		NFTDT2xidWWuaX;yZZRmeyCWTldOtU1lemm4ZX6gZ49ueGyneDDmc5Ju[XSrb36=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4MU[3O{c,OjN{NkG2O\|c9N2F-
HT-22	MUHGeY5kfGmxbjDBd5NigQ>?	MmjaNlXDqM7:TR?=	MmezNQKBmzNywrDtbY4>	MYLEUXNQ	NWfIXZc4cW6qaXLpeJMhTVKNIFHjeIl3[XSrb36gbY5lfWOnZDDifUBodHW2YX3heIU>	NEHHbYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwO\|c2Oid-MkOzNFc4PTJ:L3G+
HT-22	NGfCd5dE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NYLrWHZKOTEEoN88US=>	Ml3iNVLDqGh?	M2XHZmROW09?	MX;wdo91\WO2czDh[4FqdnO2IHfseZRidWG2ZT3pcoR2[2WmIHPlcIwh\GWjdHi=	MlPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEe3OVIoRjJ\|M{C3O\|UzRC:jPh?=
KMS-12-BM	Mn;xR5l1d3SxeHnjbZR6KEG\|c3H5	NYfWPIxJQTBiwsXN	MV:xJIg>		NXnOWW9k[myxY3vzJGJCYSBzMT23NFgzKGmwZIXj[YQhemGyaXSgZ4VtdCC\|d3XscIlv\w>?	M4DzclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUK3NVU1Lz5{M{WyO\|E2PDxxYU6=
MM.1S	NGPtT\|hEgXSxdH;4bYNqfHliQYPzZZk>	M1fDSVkxKML3TR?=	M4HudVEhcA>?		MW\icI9kc3NiQlHZJFEyNTdyOEKgbY5lfWOnZDDyZZBq\CClZXzsJJN4\WyuaX7n	NHrObJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyO\|E2PCd-MkO1NlcyPTR:L3G+
ΔN-Karpas 299	MXjDfZRwfG:6aXPpeJkhSXO\|YYm=	MWiyNOKh\|ryP	NHzFTZcyPiCq		MUPpcohq[mm2czDDSFMxNWmwZIXj[YQh[2WubDDk[YF1cA>?	M1zkTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUS1PVM5Lz5{M{W0OVk{QDxxYU6=
MEFs	NIrWRYpHfW6ldHnvckBCe3OjeR?=	NYnrVpVpOjEEoN88US=>	NX7zPXVROS9{L{SgbC=>		M3frV5N2eHC{ZYPz[ZMhXE6IzsGtbY5lfWOnZDDSTXBMOSCyaH;zdIhwenmuYYTpc44>	MmHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mke1PFEoRjJ\|N{K3OVgyRC:jPh?=
MEFs	NFzjZo1EgXSxdH;4bYNqfHliQYPzZZk>	M3m1VlIwPi9{MDFOwG0>	MkD2NVghcA>?		MUjpcohq[mm2czDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGhiaX6gVoVtSSCNTzDNSWZ{	M4m1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K3OVgyLz5{M{eyO\|U5OTxxYU6=
RMS13	MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NIDadIU1OOLCid88[{9udMLi	M{fx[lI1KGh?		NESyWFhz\XOldXXzJGdZOTVvMEewMYlv\HWlZXSgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gQ>?	M1jjUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{S0Nlk3Lz5{M{e0OFI6PjxxYU6=
TE671	NWryRYt2S2WubDDWbYFjcWyrdImgRZN{[Xl?	NEDw[Vc1OOLCid88[{9udMLi	NWPFe5RwOjRiaB?=		MlHxdoV{[3WnczDHXFE2NTB5MD3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2NEK5Okc,OjN5NESyPVY9N2F-
U87	NGL3RYVHfW6ldHnvckBCe3OjeR?=	MVixJI1ud2xxTB?=	M4HmUlEvPS1\|IHi=		Mlnqd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBTUVBvMTDjZZV{\WRiYomgd4hqc2:waX6=	MlnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEC0OFEoRjJ\|OESwOFQyRC:jPh?=
C6	MnLUSpVv[3Srb36gRZN{[Xl?	MmP1NUBudW:uL1y=	NX:xfFcxOS53LUOgbC=>		MVzzeZBxemW\|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJKWC1zIHPheZNm\CCkeTDzbIlsd26rbh?=	NYHRTFNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFA1PDFpPkKzPFQxPDRzPD;hQi=>
U87	NU\neWhuS3m2b4TvfIlkcXS7IFHzd4F6	MnHzNUBudW:uL1y=	M1H6eFMhcA>?		NFjyOIJjdG:la4Ogd4hqc2:waX6gbY5lfWOnZDDu[YNzd3Orcx?=	NFvWW4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0NFQ1OSd-MkO4OFA1PDF:L3G+
C6	NWXYXFRCS3m2b4TvfIlkcXS7IFHzd4F6	MnnmNUBudW:uL1y=	NXrQOGZvOyCq		NEjGVWVjdG:la4Ogd4hqc2:waX6gbY5lfWOnZDDu[YNzd3Orcx?=	MmDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEC0OFEoRjJ\|OESwOFQyRC:jPh?=
U87	NXe1W41SS2WubDDWbYFjcWyrdImgRZN{[Xl?	Ml\sNUBudW:uL1y=	NUXDNpdZOyCq		MXPheJRmdnWjdHXzJHNpcWuxbnnuJIlv\HWlZXSg[4xqd22jIHPlcIwh\GWjdHi=	NVOzZnU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFA1PDFpPkKzPFQxPDRzPD;hQi=>
C6	NHPYVmdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MWSxJI1ud2xxTB?=	M173XFMhcA>?		M3LmdoF1fGWwdXH0[ZMhW2ira3;ubY4hcW6mdXPl[EBodGmxbXGgZ4VtdCCmZXH0bC=>	NWPqSlVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFA1PDFpPkKzPFQxPDRzPD;hQi=>
L929	MV3GeY5kfGmxbjDBd5NigQ>?	NY[5[GhwPcLizsznM41t	MVOyOOKhcA>?		M1[0VYJtd2OtczD6WmFFKGmwZIXj[YQhdmWlcn;weI9{cXNiYX7kJIF2fG:yaHHnfS=>	NV7CZWdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFE4PjlpPkKzPVQyPzZ7PD;hQi=>
L929	MmfrSpVv[3Srb36gRZN{[Xl?	NE\QOGEzyqEQvHevcYzDqA>?	MWCyOOKhcA>?		NXTHNVE3eHKxbX;0d{Bk[XOyYYPlMVYhMHB{MDmgZYN1cX[rdImgZY5lKHC{b3Phd5Bie2VvNjDjcIVifmGpZR?=	MlHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NEG3OlkoRjJ\|OUSxO\|Y6RC:jPh?=
L929	NGDvUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOyM\|XDqM7:Zz;tcOKh	NGrNfJEzPMLiaB?=		NELEdopz\X[ncoPld{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG\|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ>	NVjYd3BjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFE4PjlpPkKzPVQyPzZ7PD;hQi=>
L929	NInEe2lHfW6ldHnvckBCe3OjeR?=	NEHF[20zNzYEoN88[{9udMLi	NH;kPWszPMLiaB?=		MnLQdoV3\XK\|ZXSgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTOSu6yKGGub37lJIF{KHenbHygZZMhXE6IzsJCpEvDqHqYQVS=	NH\Sc2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m0NVc3QSd-MkO5OFE4Pjl:L3G+
NRK-52E	MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MVSyNEDPxE1?	M3u3[lI1KGh?		M3fYd4lvcGmkaYTzJIlv[3KnYYPl[EBFenBzIIDyc5RmcW5iZYjwdoV{e2mxbjDh[pRmeiCWTl[t{tEhW3SrbYXsZZRqd25iYX7kJGFVWCCGZYDs[ZRqd25?	NF[0e2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1NVg1PSd-MkSzOVE5PDV:L3G+
NRK-52E	M3;KbGNmdGxiVnnhZoltcXS7IFHzd4F6	MWOyNEDPxE1?	M1PkNVI1KGh?		NInLNJpqdmO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiVF7GMe6yKFO2aX31cIF1cW:wIHHu[EBCXFBiRHXwcIV1cW:w	Mn\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NUG4OFUoRjJ2M{WxPFQ2RC:jPh?=
NRK-52E	Mn\oR4VtdCCYaXHibYxqfHliQYPzZZk>	M12z[\|IxKM7:TR?=	M4jQdFI1KGh?		NFLHSGhxem:2ZXP0d{Bk\WyuczDmdo9uKGOnbHyg[IVifGhiY3H1d4VlKGK7IHnzZ4hmdWmjIHnubpVzgQ>?	NEfrUGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1NVg1PSd-MkSzOVE5PDV:L3G+
AGS	M1LSWGNmdGxiVnnhZoltcXS7IFHzd4F6	NXXpbGVXPjEkgJpOwI0>	NH;6SnAy6oDLaB?=		MlyxdJJmfmWwdIOgd4hqc2:waX6tbY5lfWOnZDDj[YxtKGSnYYTo	Mn3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NkOxPVkoRjJ2NE[zNVk6RC:jPh?=
L-540	MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MUO2NQKBkc7:bR?=	NHPIR5Uy6oDLaB?=		M1W2NpJm\HWlZYOgeIhmKEerdnnuc5N1[XRxU3;yZYZmdmmkLXnu[JVk\WRiY3XscEBl\WG2aB?=	NWrRZm55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlE2OTlpPkK0OVYyPTF7PD;hQi=>
L-540	NH6wUFNHfW6ldHnvckBCe3OjeR?=	NFPxe2Y3OOLCid88cS=>	M{LGelHjiImq		NEe5PIFxemW4ZX70d{B1cGVibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBl\XCxbHHybZpifGmxbh?=	MoLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NkG1NVkoRjJ2NU[xOVE6RC:jPh?=
L-540	NFm1doZHfW6ldHnvckBCe3OjeR?=	M1LzfFYx6oDLzszt	MVOx5qCKcA>?		NVPNRXZGeHKndnXueJMhfGinIHflcoVz[XSrb36gc4YhWk:V	M{PuNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[xOVE6Lz5{NEW2NVUyQTxxYU6=
SK-Hep1	MUfGeY5kfGmxbjDBd5NigQ>?	NF:yW4w3OOLCid88UeKh	NFrtb20yQOLCiXi=		MVTicI9kc3QEoN8yMYxieGGlaH;u[U1u\WSrYYTl[EBRSVJiYXPjeY12dGG2aX;uJIFv\CCDSV[geJJidnOub3PheIlwdiC2bzD0bIUh[3m2b4PvcOKh	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|Mk[wNkc,OjR6M{K2NFI9N2F-
SK-Hep1	MVTGeY5kfGmxbjDBd5NigQ>?	M4jOdVYx6oDLzszNxsA>	M4S5RVE56oDLaB?=		MXLpcohq[mm2czFOtk1N[XCjY3jvcoUucW6mdXPl[EBt\WGtYXflJI9nKEiPR1KtNeKh	M33LfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOyOlAzLz5{NEizNlYxOjxxYU6=
SK-Hep1	NEnWUnFHfW6ldHnvckBCe3OjeR?=	MmXROlDjiIoQvF5CpC=>	MXKxPQKBkWh?		Mn;aZoxw[2u\|wrFOtk1t[XCjY3jvcoUucW6mdXPl[EBud3KyaH;sc4dq[2GuIHPoZY5o\SxiY3XscEBl\WG2aDDhcoQhWElidYD0ZYtm	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|Mk[wNkc,OjR6M{K2NFI9N2F-
OHC	MnjNSpVv[3Srb36gRZN{[Xl?	MXGzNFDjiIoQvF2=		MnPFSG1UVw>?	NEn3eVBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDhdI9xfG:2aXOgU2hEeyC5aYToc5V1KGGudHXybY5oKHSqZTDs[ZZmdHNib3[gR2M5KGGodHXyJI5wcXOnIHX4dI9{fXKn	NGDpPWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFc{PCd-MkS4O\|Q4OzR:L3G+
OHC	MlmzSpVv[3Srb36gRZN{[Xl?	M2HSUlMxOOLCid88US=>		NUDrXlRjTE2VTx?=	M{\ye4RqdWmwaYPo[ZMhdm:rc3WtbY5lfWOnZDDBUXBMKGGldHn2ZZRqd25?	M4PkTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0O\|M1Lz5{NEi3OFc{PDxxYU6=
OHC	NHe5[phHfW6ldHnvckBCe3OjeR?=	NH7HVlA{ODEkgJpOwG0>		NFfpZ5JFVVOR	NIPVU5hz\XO3bITzJIlvKGFicnXkeYN1cW:wIH;mJI5wcXOnLXnu[JVk\WRiUlnQNUBidmRiUlnQN{BqdW23bn;mcJVwemW\|Y3XuZ4U>	MoHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{S3N\|QoRjJ2OEe0O\|M1RC:jPh?=
OHC	MXzGeY5kfGmxbjDBd5NigQ>?	M32wWFMxOOLCid88US=>		M4jVUWROW09?	NHnRR4hl\WO{ZXHz[ZMhdm:rc3WtbY5lfWOnZDDze49tdGWwIH71Z4xmccLi	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEezOEc,OjR6N{S3N\|Q9N2F-
OHC	MUDGeY5kfGmxbjDBd5NigQ>?	NV;WUXlUOzBy4pEJ{txO		MnvLSG1UVw>?	NIDZfGhqdmO{ZXHz[ZMhdm:rc3WtbY5lfWOnZDDjc45l\W6\|ZXSgcpVkdGWr	NV\DOohIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|Q4OzRpPkK0PFc1PzN2PD;hQi=>
Huh7	MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MXK1NEDDvU1?	NWHae\|RJOjRxNEigbC=>	Mo\lSG1UVw>?	NHTnRWdxemW4ZX70d{Bk\WyuIHTlZZRpKG:oIILB[GhEXiClbz3pcoZm[3SnZDDIeYg4KGOnbHzz	M3jtOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUezNlQxLz5{NEm3N\|I1ODxxYU6=
L929	MoSwR4VtdCCYaXHibYxqfHliQYPzZZk>	MU[zNOKh\|ryP	M3m3S\|HDqGh?		M{nFd4lvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPs[YF3[WenIH;mJHRweG9iSR?=	MoDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyOUW3OFIoRjJ3MEm1O\|QzRC:jPh?=
L929	MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mli3N\|DDqM7:TR?=	M2rnSlHDqGh?		Mmn5bY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRibH;zd{Bw\iClZXzsJJZq[WKrbHn0fS=>	M3r0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEm1O\|QzLz5{NUC5OVc1OjxxYU6=
L929-A	MXvGeY5kfGmxbjDBd5NigQ>?	M3;GW\|UxyqEQvF5CpC=>	MnjkNVIhcA>?		NFmzVWZqdmirYnn0d{B1cGViVF7G{tEucW6mdXPl[EBtd3O\|IH;mJI1qfG:laH;u[JJq[WxibXXtZpJidmVicHXycYVi[mmuaYT5	NGLycVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO5PFU1OCd-MkWzPVg2PDB:L3G+
L929	M{nE[2Z2dmO2aX;uJGF{e2G7	Mn24OVDDqM7:TdMg	NVnxWmVIOTJiaB?=		M{nveYlvcGmkaYTzJHRPTs7zLXnu[JVk\WRiQnnkJINt\WG4YXfl	NVLDVnZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPVg2PDBpPkK1N\|k5PTRyPD;hQi=>
L929-N	NIHMellHfW6ldHnvckBCe3OjeR?=	MkPBOVDDqM7:TdMg	NIH3SVgyOiCq		M3jYSIJtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiQ3HzdIF{\S1\|IHHu[EBRSVKS	M3HsWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{m4OVQxLz5{NUO5PFU1ODxxYU6=
L929-A	MXnGeY5kfGmxbjDBd5NigQ>?	NVnwN\|l4PTEEoN88UeKh	MoHFNVIhcA>?		MnG3Zoxw[2u\|IITo[UBkdGWjdnHn[UBw\iCFYYPwZZNmNTNiYX7kJHBCWlB?	MmXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|OUi1OFAoRjJ3M{m4OVQxRC:jPh?=
L929-N	NYLPWHlzS2WubDDWbYFjcWyrdImgRZN{[Xl?	MXK1NOKh\|ryPwrC=	Mk\SNlQhcA>?		M4PWRYJtd2OtczDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh?	M33HXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{m4OVQxLz5{NUO5PFU1ODxxYU6=
L929-A	M3;1WmNmdGxiVnnhZoltcXS7IFHzd4F6	NYrxZWFMPTEEoN88UeKh	NEP3U\|gzPCCq		MWHicI9kc3NiVF7G{tEucW6mdXPl[EBk\WyuIHTlZZRp	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN7OEW0NEc,OjV\|OUi1OFA9N2F-
KMS-12-PE	MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MX:2NEDPxE1?	MlniOUBp		NUnVRpI5cW6qaXLpeJMhW0iNLXnu[JVk\WRiY3XscEBl\WG2aB?=	NVHufnpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|AxQThpPkK1OVMxODl6PD;hQi=>
SGC-7901	MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mkn1N\|DDqM7:TR?=	Mk\ZNeKhcA>?		NHuwVmF{fXCycnXzd4V{KG:6YXzpdIxifGmwLX3l[IlifGWmIHPlcIwh\GWjdHi=	NILtbpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2O\|A4Pid-MkW3OlcxPzZ:L3G+
BxPC-3	MUHGeY5kfGmxbjDBd5NigQ>?	NFvaRmozOCEQvF2=	NXjLSoxuOjRiaB?=		NITlWmtl\WO{ZXHz[ZMhfGinIHXhdox6KG6nY4LveIlkKGOnbHzz	M{X5ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MECwOlA4Lz5{NkCwNFYxPzxxYU6=
MiaPaCa-2	MnPSSpVv[3Srb36gRZN{[Xl?	NXjyT29vOjBizszN	MnLuNlQhcA>?		NU\GcHly\GWlcnXhd4V{KHSqZTDlZZJtgSCwZXPyc5Rq[yClZXzsdy=>	NWDGVnV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFA3ODdpPkK2NFAxPjB5PD;hQi=>
NCI-H28	M{\TZmNmdGxiVnnhZoltcXS7IFHzd4F6	M{mxflExyqEQvF2=	MVyyOOKhcA>?		MnG4dJJmfmWwdIOgSGFRTS2rbnT1Z4VlKHKnZIXjeIlwdiCxZjDOR2kuUDJ6IHPlcIwhfmmjYnnsbZR6yqB?	MmLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMESxN\|goRjJ4MEC0NVM5RC:jPh?=
BMDM	NIS0RoxHfW6ldHnvckBCe3OjeR?=	NEnMVGgyOMLizszN	MYmzNOKhdWmw		MWLwdo91\WO2czDj[YxteyCocn;tJHRCU0lvaX7keYNm\CCORFigdoVt\WG\|ZR?=	NV[2WVQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPFE3ODFpPkK2N\|gyPjBzPD;hQi=>
MEFs	M2PKc2NmdGxiVnnhZoltcXS7IFHzd4F6	MWCxNQKBkc7:TR?=	MVu0PEBp	MmXYSG1UVw>?	NVzH[3d5cW6qaXLpeJMhgl[DRD3wdo9ud3SnZDDk[YF1cCCxZjDDUm9VOy2mZYDs[ZRm\CCPRV\z	NYfKWnRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0N\|c4QDlpPkK2OFM4Pzh7PD;hQi=>
A549	M1\oRmNmdGxiVnnhZoltcXS7IFHzd4F6	Ml;pOVDDqM7:TR?=	MofmNlTDqGh?		MUPpcohq[mm2czDNUXMucW6mdXPl[EBk\WyuIHTlZZRp	NELsSFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS3NlczOyd-Mk[0O\|I4OjN:L3G+
Jurkat T	MX;O[YNzd3C2b4Ppd{Bie3OjeR?=				MVLJcohq[mm2aX;uJI9nKFSQRj3hcJBp[S2rbnT1Z4VlKG6nY4LvdJRwe2m\|IHnuJGZCTERvZHXmbYNq\W62IHj1cYFvKEq3cnvheEBVKGOnbHzzMEBGSzVyIE2gNE4xPSEQvF2u	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4N{C5OEc,OTh2NkewPVQ9N2F-
Jurkat	NX7uNXZFTnWwY4Tpc44h[XO\|YYm=				M3W5TWlvcGmkaYTpc44hd2ZiZX7kc4dmdm:3czDSTXAyKGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iSoXyb4F1KGOnbHzzMEBGSzVyIE2gNE4yQDJizszNMi=>	NULaOIxvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NFg4OTNpPkG4OFA5PzF\|PD;hQi=>
Sf9	NF7XOVBHfW6ldHnvckBie3OjeR?=		NIrzXGE{OCCvaX7z		Ml21TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCJU2St[pV{\WRiUlnQT\|EhMDFidH:gOFk4KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JHNnQSClZXzsd{BqdiCycnXz[Y5k\SCxZjCzNnAu\2GvbXGtRXRRKGGodHXyJFMxKG2rboOgZpkh[XW2b4Lh[Ilw\3KjbT3iZZNm\CCZZYP0[ZJvKGKub4SgcYV1cG:mLDDJR\|UxKD1iMD6xPFIh\|ryPLh?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
Jurkat T	NYPP[nIzVmWlcn;weI9{cXNiYYPzZZk>				MUTF[oZm[3SrdnWgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CCob4KgbY5pcWKrdHnvckBw\iCwZXPyc5B1d3OrczDpckBHSUSGIHTl[olkcWWwdDDKeZJs[XRiVDDj[YxteyC2cnXheIVlKHerdHigWG5HNWGucHjhMEBGSzVyIE2gNE41QSEQvF2u	Ml;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZzNUO4OFAoRjF4MUWzPFQxRC:jPh?=
Jurkat	M1TWbG5m[3KxcITvd4l{KGG\|c3H5				MkX6TY5pcWKrdHnvckBw\iClZXzseYxieiCwZXPyc5B1d3OrczDpckBVVk[jbIDoZUB1emWjdHXkJGZCTERiZHXmbYNq\W62IHj1cYFvKEq3cnvheEBk\WyuczygSWM2OCB;IECuOFkh\|ryPLh?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDRyOEexN{c,OTh2MEi3NVM9N2F-
Jurkat T	MknvUoVkem:ydH;zbZMh[XO\|YYm=	M2nVTVMxKHWP	NXzUVGQ2OjRiaILz		MXjJcohq[mm2aX;uJI9nKG6nY4LvdJRwe2m\|IHnuJHRPTi2jbIDoZU1qdmS3Y3XkJIh2dWGwIFr1dotifCCWIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGG2IEOwJJVOKGGodHXyJFI1KGi{cx?=	NVrxe5QzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0OlcxQTRpPkG4OFY4ODl2PD;hQi=>
L929	MYPO[YNzd3C2b4Ppd{Bie3OjeR?=	NWKzPG9pOzBidV2=	MWqyOEBpenN?		MnXSTY5pcWKrdHnvckBw\iCwZXPyc5B1d3OrczDpckB7XkGGLXnu[JVk\WRibX;1d4UhVDl{OTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjdDCzNEB2VSCjZoTldkAzPCCqcoO=	MmP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NkewPVQoRjF6NE[3NFk1RC:jPh?=
L929	NEjhe3hP\WO{b4D0c5NqeyCjc4PhfS=>	MXGzNEB2VQ>?	NVe2Z\|NPOjRiaILz		NU\XXVJOUW6qaXLpeIlwdiCxZjDu[YNzd3C2b4Ppd{BqdiCWTl[tZYxxcGFvaX7keYNm\CCvb4Xz[UBNQTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGG2IEOwJJVOKGGodHXyJFI1KGi{cx?=	NYnJTphWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0OlcxQTRpPkG4OFY4ODl2PD;hQi=>
3T3	NV3JSFVzS2WubDDk[YF1cCCjc4PhfS=>		M4DMW\|I1KGi{cx?=		NH;yV5FKdmirYnn0bY9vKG:oIHTlZZRpKHKnY3XweI9zKHOrZ37hcIlv\yCvZXTpZZRm\CCwZXPyc5Rq[yClZXzsJIRm[XSqIHnuJI1wfXOnIEPUN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliQWTQJIJie2WmII\pZYJqdGm2eTDhd5NigSCrbjDwdoV{\W6lZTDv[kBVVk[jbIDoZUBidmRiem\BSE5ndWt?	M2mxRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
3T3	NFm5blFE\WyuIHTlZZRpKGG\|c3H5		MVWyOEBpenN?		MX\Jcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4TpZ{Bk\WyuIHTlZZRpKGmwIH3veZNmKDOWMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhSVSSIHLhd4VlKH[rYXLpcIl1gSCjc4PhfUBqdiCycnXz[Y5k\SCxZjDGZZNNKGGwZDD6WmFFNm[vax?=	NFfCPJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
MEF	NHu2UFFE\WyuIHTlZZRpKGG\|c3H5		M1P6c\|E3KGi{cx?=		MnLOTY5pcWKrdHnvckBw\iCmZXH0bEBz\WOncITvdkB{cWewYXzpcochdWWmaXH0[YQhdmWlcn;0bYMh[2WubDDk[YF1cCCrbjDTWlQxKHS{YX7z[o9zdWWmIH3veZNmKE2HRjDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkAyPiCqcoOgZpkhSVSSIHLhd4VlKH[rYXLpcIl1gSCjc4PhfUBqdiCycnXz[Y5k\SCxZjDUUmZidHCqYTygR2hZKGGwZDD6WmFFNm[vax?=	NIr5OYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
IEC18	M2L5V2NmdGxiZHXheIgh[XO\|YYm=				NGjVZlRKdmirYnn0bY9vKG:oIHTlZZRpKHKnY3XweI9zKHOrZ37hcIlv\yCvZXTpZZRm\CCwZXPyc5Rq[yClZXzsJIRm[XSqIHnuJJJifCCLRVOxPEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDpckBxemW\|ZX7j[UBw\iCWTl\hcJBp[SCjbnSgfnZCTC6obXu=	M4ns[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
HL60	M1XPdGNmdGxiZHXheIgh[XO\|YYm=				MX;Jcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4TpZ{Bk\WyuIHTlZZRpKGmwIHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliaX6gdJJme2WwY3Wgc4YhXE6IYXzwbIEh[W6mIIrWRWQv\m2t	M2X6WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
L929	M{OxPWNmdGxiZHXheIgh[XO\|YYm=		MlfSNlQhcHK\|		Mn;ETY5pcWKrdHnvckBw\iCmZXH0bEBz\WOncITvdkB{cWewYXzpcochdWWmaXH0[YQhdmWlcn;0bYMh[2WubDDk[YF1cCCrbjDtc5V{\SCOOUK5JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSCDVGCgZoF{\WRidnnhZoltcXS7IHHzd4F6KGmwIIDy[ZNmdmOnIH;mJHRPTmGucHjh	MkjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	NYTGVVY6VmWlcn;zbZMh[XO\|YYm=				NYfDWG9WUW6qaXLpeIlwdiCxZjDu[YNzd3OrczDpckBpfW2jbjDKeZJs[XRiY3XscJMh[XO\|ZYPz[YQh[XNiboXjcIVieiClb37k[Y5{[XSrb36gZpkh[nKrZ3j0JIZq\WymIH3pZ5Jwe2OxcImgbY4heHKnc3XuZ4Uhd2ZiRnHzUEwhS0i[IHHu[EB7XkGGLX\tby=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjRyOECwPEc,OTZ2MEiwNFg9N2F-
Jurkat	Mm\2UoVkem:\|aYOgZZN{[Xl?				M{LYbmlvcGmkaYTpc44hd2ZibnXjdo9{cXNiaX6gbJVu[W5iSoXyb4F1KGOnbHzzJIF{e2W\|c3XkJIF{KG:{Z3Hu[Yxt\SC\|d3XscIlv\yCkeTDidolocHRiZnnlcIQhdWmlcn;zZ49xgSCrbjDwdoV{\W6lZTDv[kBH[XOOLDDDTHgh[W6mIIrWRWQu\m2t	NUjnTZVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	MXrO[YNzd3OrczDhd5NigQ>?				M4\BcmlvcGmkaYTpc44hd2ZibnXjdo9{cXNiaX6gbJVu[W5iSoXyb4F1KGOnbHzzJIF{e2W\|c3XkJIF{KGWjcnz5JIxwe3Nib3[gdIxie22jIH3lcYJz[W6nIHnueIVoemm2eTDifUBjemmpaISg[olmdGRibXnjdo9{[2:yeTDpckBxemW\|ZX7j[UBw\iCIYYPMMEBEUFhiYX7kJJpXSURvZn3r	M1f0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
Jurkat	NUfDNWNpVmWlcn;zbZMh[XO\|YYm=				NF7OUpNKdmirYnn0bY9vKG:oIH7lZ5Jwe2m\|IHnuJIh2dWGwIFr1dotifCClZXzsd{Bie3Onc4Pl[EBieyCjcIDlZZJidmOnIH;mJJRz[W6\|bIXj[Y51KGO7dH;zc4whcW5icILld4Vv[2Vib3[gSoF{VCxiQ1jYJIFv\CC8VlHEMYZucw>?	NGS2TIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
Jurkat	M{\IcG5m[3Kxc3nzJIF{e2G7				MlPwTY5pcWKrdHnvckBw\iCwZXPyc5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOg[IVncWOrZX70JIlvKE[DRFSgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDueYNt\WG{IHPvcoRmdnOjdHnvckBjgSCkcnnnbJQh\mmnbHSgcYlkem:\|Y3;wfUBqdiCycnXz[Y5k\SCxZjDUUmZidHCqYR?=	NI[zTXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
Jurkat	NIfLV21P\WO{b4Ppd{Bie3OjeR?=				MYnJcohq[mm2aX;uJI9nKG6nY4Lvd4l{KGmwIHj1cYFvKEq3cnvheEBk\WyuczDk[YZq[2mnboSgbY4hTkGGRDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIH;y[4Fv\WyuZTDze4VtdGmwZzDifUBjemmpaISg[olmdGRibXnjdo9{[2:yeTDpckBxemW\|ZX7j[UBw\iCWTl\hcJBp[Q>?	NXL6bYRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	Mn32UoVkem:\|aYOgZZN{[Xl?				MXPJcohq[mm2aX;uJI9nKG6nY4Lvd4l{KGmwIHj1cYFvKEq3cnvheEBk\WyuczDk[YZq[2mnboSgbY4hTkGGRDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXhdox6KGyxc4Ogc4YheGyjc33hJI1mdWK{YX7lJIlvfGWpcnn0fUBjgSCkcnnnbJQh\mmnbHSgcYlkem:\|Y3;wfUBqdiCycnXz[Y5k\SCxZjDUUmZidHCqYR?=	MmK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	NGn2WVRP\WO{b4Ppd{Bie3OjeR?=				NIjGV\|BKdmirYnn0bY9vKG:oIH7lZ5Jwe2m\|IHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFxeGWjcnHuZ4Uhd2ZidILhcpNtfWOnboSgZ5l1d3OxbDDpckBxemW\|ZX7j[UBw\iCWTl\hcJBp[Q>?	NHvXN3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
U937	NHLBVZZE\WyuIHTlZZRpKGG\|c3H5		NULGUYoyPDhiaILz		MVvJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIGW5N\|ch[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFHUVEBj[XOnZDD2bYFjcWyrdImgZZN{[XliaX6gdJJme2WwY3Wgc4YhXE6IYXzwbIEh[W6mIIrWRWQu\m2t	Mk\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
3T3	NIP4VoFE\WyuIHTlZZRpKGG\|c3H5		MYKyOEBpenN?		M4PZbmlvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hdW:3c3WgN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDBWHAh[mG\|ZXSgeoli[mmuaYT5JIF{e2G7IHnuJJBz\XOnbnPlJI9nKFSQRnHsdIhiKGGwZDD6WmFFNW[vax?=	Mn\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	MWHD[YxtKGSnYYToJIF{e2G7		MV6yOEBpenN?		MWPJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBie3Onc4Pl[EBieyCmZXPy[YF{\WRibHX2[Yx{KG:oIGDFMYNwdmq3Z3H0[YQhVEN\|LVnJJEhifXSxcHjh[5khdWG{a3XyLUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[EBqdiCycnXz[Y5k\SCxZjDUUmZidHCqYR?=	Mln3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
L929	MVTD[YxtKGSnYYToJIF{e2G7		MV2yOEBpenN?		M4DCemlvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hdW:3c3WgUFkzQSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\WRibHX2[Yx{KG:oIGDFMYNwdmq3Z3H0[YQh[XW2b4DoZYd6KG2jcnvldkBNSzNvSVmgZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3SgbY4heHKnc3XuZ4Uhd2ZiVF7GZYxxcGF?	NF:zd5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
3T3	MWrD[YxtKGSnYYToJIF{e2G7		M{TESlI1KGi{cx?=		M4Wxd2lvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hdW:3c3WgN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNm\CCuZY\lcJMhd2ZiUFWtZ49vcnWpYYTl[EBifXSxcHjh[5khdWG{a3XyJGxEOy2LSTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZDDpckBxemW\|ZX7j[UBw\iCWTl\hcJBp[SCjbnSgfnZCTC2obXu=	M2jBfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFA5Lz5zNkSwPFAxQDxxYU6=
3T3	NELvUXRE\WyuIHTlZZRpKGG\|c3H5		Mn7QNlQhcHK\|		MUPJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJI1wfXOnIEPUN{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[YQhdGW4ZXzzJI9nKFCHLXPvcop2\2G2ZXSgZZV1d3CqYXf5JI1iemuncjDMR\|MuUUliYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2RiaX6gdJJme2WwY3Wgc4YhTmG\|TDDhcoQhgl[DRD3mcYs>	MnXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
3T3	NITne3NE\WyuIHTlZZRpKGG\|c3H5		Mn\zNlQhcHK\|		M3PsdGlvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hdW:3c3WgN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNm\CCuZY\lcJMhd2ZiUFWtZ49vcnWpYYTl[EBifXSxcHjh[5khdWG{a3XyJGxEOy2LSTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZDDpckBxemW\|ZX7j[UBw\iC{YYDhcZlkcW5?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjRyOECwPEc,OTZ2MEiwNFg9N2F-
Jurkat	M2jJXGNmdGxiZHXheIgh[XO\|YYm=		Mn;0OFghcHK\|		MoG5TY5pcWKrdHnvckBw\iCmZXH0bEBz\WOncITvdkB{cWewYXzpcochdWWmaXH0[YQhdmWlcn;weI91cWNiY3XscEBl\WG2aDDpckBpfW2jbjDKeZJs[XRiY3XscJMh\GWoaXPp[Y51KGmwIF\BSGQh[W6mIHX4dJJme3OrbnegSmtDWDF{LXLhd4VlKGSrbXXybZpifGmxbjDkc41icW5iYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KE[DQ2OgbY4heHKnc3XuZ4Uhd2ZiQWCxOVExNCC8VlHEMYZucw>?	NIm3PWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
Jurkat	M{K0W2NmdGxiZHXheIgh[XO\|YYm=		NIHZVFg1QCCqcoO=		M37qPWlvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hcHWvYX6gTpVzc2G2IHPlcIx{KGSnZnnjbYVvfCCrbjDGRWRFKGGwZDDlfJBz\XO\|aX7nJHJKWCCtaX7hd4Uh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGZCS1NiaX6gdJJme2WwY3Wgc4YhSVBzNUGwMEB7XkGGLX\tby=>	NXLySnkxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	M4H0fGNmdGxiZHXheIgh[XO\|YYm=		M{[xPFQ5KGi{cx?=		NYH6[2R{UW6qaXLpeIlwdiCxZjDk[YF1cCC{ZXPldJRweiC\|aXfuZYxqdmdibXXkbYF1\WRibnXjdo9xfG:2aXOgZ4VtdCCmZXH0bEBqdiCqdX3hckBLfXKtYYSgZ4VtdHNiZHXmbYNq\W62IHnuJGZCTERiYX7kJIV5eHKnc4PpcochWkmSIFu0OW0hdXW2YX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGmwIIDy[ZNmdmOnIH;mJGFROTVzMDygfnZCTC2obXu=	MkKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwNFgoRjF4NEC4NFA5RC:jPh?=
Jurkat	M1HT[mNmdGxiZHXheIgh[XO\|YYm=		MXu0PEBpenN?		MVTJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBidmRiZYjwdoV{e2mwZzDSTXAhc2mwYYPlJIRwdWGrbjDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliRlHDV{BqdiCycnXz[Y5k\SCxZjDBVFE2OTBuIIrWRWQu\m2t	NXW3V5piRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	M2PBUWNmdGxiZHXheIgh[XO\|YYm=		MV[0PEBpenN?		MVLJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBidmRiZYjwdoV{e2mwZzDGT2JROTJvYnHz[YQh\GmvZYLpfoF1cW:wIHTvcYFqdiCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhTkGFUzDpckBxemW\|ZX7j[UBw\iCDUEG1NVA>	NYjOOmx3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Jurkat	MXXD[YxtKGSnYYToJIF{e2G7		MVu0PEBpenN?		M4L3UGlvcGmkaYTpc44hd2ZiZHXheIghemWlZYD0c5Ihe2mpbnHsbY5oKG2nZHnheIVlKG6nY4LvdJRwfGmlIHPlcIwh\GWjdHigbY4hcHWvYX6gTpVzc2G2IHPlcIx{KGSnZnnjbYVvfCCrbjDGRWRFKGGwZDDlfJBz\XO\|aX7nJHJKWCCtaX7hd4Uh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGZCS1NiaX6gdJJme2WwY3Wgc4YhSVBzNUGw	NIXiS489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFAxQCd-MU[0NFgxODh:L3G+
Jurkat	M2jnSWNmdGxiZHXheIgh[XO\|YYm=		NF7IUYQ1QCCqcoO=		MXzJcohq[mm2aX;uJI9nKGSnYYToJJJm[2WydH;yJJNq\26jbHnu[{Bu\WSrYYTl[EBv\WO{b4D0c5Rq[yClZXzsJIRm[XSqIHnuJIh2dWGwIFr1dotifCClZXzsd{Bl\W[rY3nlcpQhcW5iRlHESEBidmRiZYjwdoV{e2mwZzDSTXAhUzR3TTDteZRidnRiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KE[DQ2OgbY4heHKnc3XuZ4Uhd2ZiQWCxOVEx	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjRyOECwPEc,OTZ2MEiwNFg9N2F-
Jurkat	MlnER4VtdCCmZXH0bEBie3OjeR?=		M4fYelQ5KGi{cx?=		NYntR49bUW6qaXLpeIlwdiCxZjDk[YF1cCC{ZXPldJRweiC\|aXfuZYxqdmdibXXkbYF1\WRibnXjdo9xfG:2aXOgZ4VtdCCmZXH0bEBqdiCqdX3hckBLfXKtYYSgZ4VtdHNiZHXmbYNq\W62IHnuJGZCTERiYX7kJIV5eHKnc4PpcochWkmSIHvpcoF{\SCmb33hbY4h[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGZCS1NiaX6gdJJme2WwY3Wgc4YhSVBzNUGw	NYn1b4lCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODhpPkG2OFA5ODB6PD;hQi=>
Sf9	M1PwbGZ2dmO2aX;uJIF{e2G7				NEP2PVRKdmirYnn0bY9vKG:oIHj1cYFvKFKLUEGgT\|Q2VSCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzz	MkX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MEi3NVMoRjF6NEC4O\|E{RC:jPh?=
Jurkat	MV7DfZRweHKxdHXjeIl3\SCjc4PhfS=>	MV:zNEB2VQ>?	MXmxJIhz		NYnQZW5nS3m2b4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6\|dDDGZZNNNWmwZIXj[YQhdmWlcn;weI9{cXNiaX6gbJVu[W5iSoXyb4F1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEOwJJVOKGmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDGZZNNKHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDJyIHjyd{BjgSCDbHHtZZIh[my3ZTDhd5NigQ>?	MkTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzOVcoRjJ7NUSxN\|U4RC:jPh?=
Jurkat	M2TwXGN6fG:ycn;0[YN1cX[nIHHzd4F6	MYKzNEB2VQ>?	MkDyNUBpeg>?		NUD0R5JKS3m2b4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6\|dDDDTHgucW6mdXPl[EBv\WO{b4D0c5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[XRiM{CgeW0hcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IFPIXEB{fGmvdXzheIlwdiCkeTDBcIFu[XJiYnz1[UBie3OjeR?=	MofIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzOVcoRjJ7NUSxN\|U4RC:jPh?=
Jurkat	NV3aV5JMS3m2b4Dyc5Rm[3SrdnWgZZN{[Xl?	NIHMcoo{OCC3TR?=	MXWxJIhz		NGHaeG1EgXSxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGqtWmFFNWmwZIXj[YQhdmWlcn;weI9{cXNiaX6gbJVu[W5iSoXyb4F1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEOwJJVOKGmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDaMXZCTCC\|dHnteYxifGmxbjDifUBCdGGvYYKgZox2\SCjc4PhfS=>	M3\4RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|U4Lz5{OUW0NVM2PzxxYU6=
Jurkat	NVP5bnA4S3m2b4Dyc5Rm[3SrdnWgZZN{[Xl?	NFW1dXo{OCC3TR?=	MkXsNUBpeg>?		M{fxOWN6fG:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiRnHzUE1qdmS3Y3XkJI5m[3KxcITvd4l{KGmwIHj1cYFvKEq3cnvheEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBifCB\|MDD1UUBqdmO3YnH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nliRnHzUEB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkAzOCCqcoOgZpkheGijc3WgZ49vfHKjc4SgcYlkem:\|Y3;wfS=>	NEPm[FU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM2Pyd-Mkm1OFE{PTd:L3G+
Jurkat	M4PxXWN6fG:ycn;0[YN1cX[nIHHzd4F6	NF\lRm0{OCC3TR?=	MlW3NUBpeg>?		MXnDfZRweHKxdHXjeIl3\SCjY4Tpeol1gSCjZ3HpcpN1KEOKWD3pcoR2[2WmIH7lZ5JweHSxc3nzJIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBk\WyuII\pZYJqdGm2eTDheEA{OCC3TTDpcoN2[mG2ZXSg[o9zKDFiaIKg[o9tdG:5ZXSgZpkhS0i[IIP0bY12dGG2aX;uJIJ6KHCqYYPlJINwdnS{YYP0JI1q[3Kxc3PvdJk>	M1i0[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|U4Lz5{OUW0NVM2PzxxYU6=
Jurkat	NU\n[WxyS3m2b4Dyc5Rm[3SrdnWgZZN{[Xl?	NXToTGw{OzBidV2=	M4LVdVEhcHJ?		M3fkPGN6fG:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiWj3WRWQucW6mdXPl[EBv\WO{b4D0c5NqeyCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[XRiM{CgeW0hcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IGqtWmFFKHO2aX31cIF1cW:wIHL5JJBp[XOnIHPvcpRz[XO2IH3pZ5Jwe2OxcIm=	NY[4XYhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PTdpPkK5OVQyOzV5PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Immunofluorescence	RIP1 / RIP3 ; PubMed: 30462730 PLoS One Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.	30462730

Protocol

Kinase Assay:

^[1]

- Collapse

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-³²P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.

Cell Research:

^[2]

- Collapse

Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
Concentrations: 0.01-100 μM
Incubation Time: --
Method:
Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC₆ for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.

(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	51 mg/mL warmed (196.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Necrostatin-1 SDF

Molecular Weight	259.33
Formula	C₁₃H₁₃N₃OS
CAS No.	4311-88-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Choose Your Country or Region

By Signaling Pathways

By product type

Necrostatin-1